The role of natriuretic peptide testing in guiding chronic heart failure management: Review of available data and recommendations for use

Archives of Cardiovascular Diseases

Volumn 105, Issue 1, 2012, Pages 40-50

  Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Heart failure; Natriuretic peptides; Outcomes

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR RISK; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; MORBIDITY; MORTALITY; PATIENT CARE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SECRETION; QUALITY OF LIFE; REVIEW;

BIOLOGICAL MARKERS; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES AS TOPIC; PROTEIN PRECURSORS;

EID: 84857790646     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2011.10.007     Document Type: Review

References (51)

1. G.C. Fonarow, N.M. Albert, and A.B. Curtis Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to improve the use of evidence-based heart failure therapies in the outpatient setting (Improve HF) Circulation 122 2010 585 596
2. W.T. Abraham, P.B. Adamson, and R.C. Bourge Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial Lancet 377 2011 658 666
3. J. Brachmann, M. Bohm, and K. Rybak Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (optimization of heart failure management using optivol fluid status monitoring and carelink) Eur J Heart Fail 13 2011 796 804
4. W.F. Peacock, A. Harrison, and D. Moffa Clinical and economic benefits of using Audicor S3 detection for diagnosis and treatment of acute decompensated heart failure Congest Heart Fail 12 Suppl. 1 2006 32 36
5. F. Braunschweig, A. Fahrleitner-Pammer, and M. Mangiavacchi Correlation between serial measurements of N-terminal pro-brain-natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure Eur J Heart Fail 8 2006 797 803 (Pubitemid 44779416)
6. A.A. Chen, M.J. Wood, and D.G. Krauser NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP investigation of dyspnoea in the emergency department (PRIDE) echocardiographic substudy Eur Heart J 27 2006 839 845
7. C.R. DeFilippi, J.C. Fink, and C.M. Nass N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis Am J Kidney Dis 46 2005 35 44 (Pubitemid 40848431)
8. I.A. Khan, J. Fink, and C. Nass N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients Am J Cardiol 97 2006 1530 1534
9. H.N. Kim, and J.L. Januzzi Jr. Natriuretic peptide testing in heart failure Circulation 123 2011 2015 2019
10. P.A. Scott, P.A. Townsend, and L.L. Ng Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers Europace 13 2011 1419 1427
11. J.G. Cleland, J.J. McMurray, and J. Kjekshus Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from Corona (controlled rosuvastatin multinational trial in heart failure) J Am Coll Cardiol 54 2009 1850 1859
12. M. Kubanek, K.M. Goode, and V. Lanska The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction Eur J Heart Fail 11 2009 367 377
13. S. Masson, R. Latini, and I.S. Anand Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan heart failure trial) J Am Coll Cardiol 52 2008 997 1003
14. H.F. McIntyre Leveraging guidelines: understanding heart failure, organizing care. Commentary on the 2010 NICE chronic heart failure guideline update Eur J Heart Fail 13 2011 14 17
15. S. Masson, R. Latini, and I.S. Anand Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan heart failure (Val-HeFT) data Clin Chem 52 2006 1528 1538 (Pubitemid 44148316)
16. J.P. Araujo, A. Azevedo, and P. Lourenco Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure Am J Cardiol 98 2006 1248 1250 (Pubitemid 44739919)
17. M. Schou, F. Gustafsson, and P.H. Nielsen Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state Eur J Heart Fail 9 2007 68 74 (Pubitemid 46074482)
18. A.H. Wu Serial testing of B-type natriuretic peptide and NT-proBNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results Am Heart J 152 2006 828 834 (Pubitemid 44632969)
19. D.A. Pascual-Figal, M. Domingo, and T. Casas Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients Eur Heart J 29 2008 1011 1018 (Pubitemid 351844674)
20. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000;101:378-84.
21. I.S. Anand, L.D. Fisher, and Y.T. Chiang Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan heart failure trial (Val-HeFT) Circulation 107 2003 1278 1283 (Pubitemid 36314411)
22. C. Berry, N.F. Murphy, and G. De Vito Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker Eur J Heart Fail 9 2007 429 434 (Pubitemid 46441973)
23. G. Cioffi, L. Tarantini, and C. Stefenelli Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function J Card Fail 12 2006 608 615 (Pubitemid 44512142)
24. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675 (Pubitemid 33126822)
25. V.M. Conraads, P. Beckers, and J. Vaes Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure Eur Heart J 25 2004 1797 1805 (Pubitemid 39330230)
26. M.E. Davis, A.M. Richards, and M.G. Nicholls Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure Circulation 113 2006 977 985 (Pubitemid 43879473)
27. R.N. Doughty, G.A. Whalley, and H.A. Walsh Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN echo substudy Circulation 109 2004 201 206 (Pubitemid 38114140)
28. M. Feola, E. Menardi, and F. Ribichini Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure Med Sci Monit 9 2003 CR341 CR345
29. F.M. Fruhwald, A. Fahrleitner-Pammer, and R. Berger Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony Eur Heart J 28 2007 1592 1597 (Pubitemid 47227112)
30. F. Hartmann, M. Packer, and A.J. Coats Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol prospective randomized cumulative survival (COPERNICUS) trial Circulation 110 2004 1780 1786 (Pubitemid 39302655)
31. F. Hartmann, M. Packer, and A.J. Coats NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy Eur J Heart Fail 6 2004 343 350 (Pubitemid 38253055)
32. M. Kohno, M. Minami, and H. Kano Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left venticular hypertrophy Metabolism 49 2000 1356 1360
33. C. Passino, S. Severino, and R. Poletti Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure J Am Coll Cardiol 47 2006 1835 1839
34. A.M. Richards, R. Doughty, and M.G. Nicholls Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand heart failure group J Am Coll Cardiol 37 2001 1781 1787 (Pubitemid 32499959)
35. B. Stanek, B. Frey, and M. Hulsmann Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction J Am Coll Cardiol 38 2001 436 442 (Pubitemid 32721772)
36. T. Tsutamoto, A. Wada, and K. Maeda Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure J Am Coll Cardiol 37 2001 1228 1233
37. M. White, J.L. Rouleau, and R. Afzal Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker Ther Adv Cardiovasc Dis 3 2009 113 121
38. R.W. Troughton, C.M. Frampton, and T.G. Yandle Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (NT-BNP) concentrations Lancet 355 2000 1126 1130 (Pubitemid 30172933)
39. R. Berger, D. Moertl, and S. Peter N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study J Am Coll Cardiol 55 2010 645 653
40. J.L. Januzzi Jr., S. Rehman, and A.A. Mohammed Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction J Am Coll Cardiol 58 2011 1881 1889
41. P. Jourdain, G. Jondeau, and F. Funck Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study J Am Coll Cardiol 49 2007 1733 1739 (Pubitemid 46589928)
42. L.W. Eurlings, P.E. van Pol, and W.E. Kok Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can pro-brain-natriuretic peptide-guided therapy of chronic heart failure improve heart failure morbidity and mortality?) study J Am Coll Cardiol 56 2010 2090 2100
43. J.G. Lainchbury, R.W. Troughton, and K.M. Strangman N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial J Am Coll Cardiol 55 2009 53 60
44. H. Persson, H. Erntell, and B. Eriksson Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP-guided management of heart failure - SIGNAL-HF (Swedish Intervention study - guidelines and NT-proBNP analysis in heart failure) Eur J Heart Fail 12 2010 1300 1308
45. M. Pfisterer, P. Buser, and H. Rickli BNP-guided vs symptom-guided heart failure therapy: the Trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial JAMA 301 2009 383 392
46. M.R. Shah, R.M. Califf, and A. Nohria The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure J Card Fail 17 2011 613 621
47. G.M. Felker, V. Hasselblad, and A.F. Hernandez Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials Am Heart J 158 2009 422 430
48. P. Porapakkham, H. Zimmet, and B. Billah B-type natriuretic peptide-guided heart failure therapy: a meta-analysis Arch Intern Med 170 2010 507 514
49. J.L. Januzzi Jr. Use of biomarkers to "guide" care in chronic heart failure: what have we learned (so far)? J Card Fail 17 2011 622 625
50. A. Bhardwaj, S.U. Rehman, and A. Mohammed Design and methods of the pro-B-type natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) Study Am Heart J 159 2010 532 5380
51. L.H. Cavallari, and N.A. Limdi Warfarin pharmacogenomics Curr Opin Mol Ther 11 2009 243 251